Signal Desk · Companies

Biocon wins USFDA approval for cancer biosimilar Pebrilzo

2026-11-16 · 1 source · Business Standard Companies

In short

Biocon has got USFDA approval for Pebrilzo, its fifth cancer biosimilar. The company also said it has a global settlement and licence deal with Genentech.

That agreement allows Pebrilzo's earliest licensed US launch in 2028. It gives Biocon a clearer route to sell the drug in the US.

What the reporting says

Biocon secured USFDA approval for Pebrilzo, its fifth cancer biosimilar, and said it has a global settlement and licence agreement with Genentech. The deal allows Pebrilzo's earliest licensed US launch in 2028. The approval and agreement strengthen Biocon's biosimilar pipeline and set a clearer path for the drug's US rollout.

Why it matters

Biocon received USFDA approval for Pebrilzo and said it reached a global settlement and licence agreement with Genentech. The agreement sets up the earliest licensed US launch for 2028, giving the company a defined path for a later market entry. The news is important for Biocon's biosimilar portfolio and its cancer treatment pipeline.

Touches: Biocon, Genentech, Healthcare, Companies, Markets

Sources